6-trifluorometyl-2-(4-trifluoromethyl-phenyl)-1,8-dithia-3-aza-dibenzo[e, h]azulene | 629641-75-4

• 分子结构分类: 有机化合物
• 英文名称: 6-trifluorometyl-2-(4-trifluoromethyl-phenyl)-1,8-dithia-3-aza-dibenzo[e, h]azulene
• 英文别名: 10-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]-3,13-dithia-5-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),2(6),4,7(12),8,10,14,16-octaene
• CAS: 629641-75-4
• 化学式: C₂₃H₁₁F₆NS₂
• 分子量: 479.469
• InChiKey: MGQZHNMLZQHEBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  32
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  6-trifluorometyl-2-(4-trifluoromethyl-phenyl)-1,8-dithia-3-aza-dibenzo[e, h]azulene 以84%的产率得到3-(1-hydroxycarbamoyl-heptylsulfinyl)-benzoic acid hydroxyamide
  参考文献：
  名称：

  N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or sulfonyl) 3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

  摘要：

  翻译结果如下： 基质金属蛋白酶（MMps）是一组与连接组织和基底膜病理破坏有关的酶。这些含有锌的内切肽酶包括几个酶亚组，如胶原酶、溶素和明胶酶。肿瘤坏死因子-α转化酶（TACE），一种促炎症细胞因子，催化膜结合的肿瘤坏死因子-α前体蛋白形成肿瘤坏死因子-α。因此，人们预期基质金属蛋白酶（MMPs）和TACE的小分子抑制剂可能具有治疗多种疾病状态的前景。本发明提供了低分子量、非肽类的基质金属蛋白酶（MMPs）和肿瘤坏死因子-α转化酶（TACE）的抑制剂，用于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周病、骨病、糖尿病（胰岛素抵抗）和HIV感染。本发明中的化合物由以下公式表示： 其中R1、R2、R3和R4在本说明书中有所描述。

  公开号：

  US06342508B1

文献信息

• 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
  申请人：Mercep Mladen

  公开号：US20060111340A1

  公开（公告）日：2006-05-25

  The present invention relates to derivatives of 1-thia-3-aza-dibenzoazulene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.

  本发明涉及1-硫-3-氮杂双苯并吖啶类的衍生物，其药理学上可接受的盐和溶剂，以及其制备过程和中间体，以及它们的抗炎作用，特别是抑制肿瘤坏死因子-α（TNF-α）的产生和抑制白细胞介素-1（IL-1）的产生，以及它们的镇痛作用。
• USE OF 1-THIA-DIBENZO E,H AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
  申请人：PLIVA-ISTRAZIVACKI INSTITUT d.o.o.

  公开号：EP1684751A1

  公开（公告）日：2006-08-02
• 1-Thia-3-aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
  申请人：Mercep Mladen

  公开号：US20070078123A1

  公开（公告）日：2007-04-05

  The present invention relates to the use of derivatives from the group of 1-thia-3-aza-dibenzo[e,h]azulenes and of their pharmaceutically acceptable salts and solvates in a pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other neurotransmitters.
• US7262302B2
  申请人：——

  公开号：US7262302B2

  公开（公告）日：2007-08-28
• [EN] USE OF 1-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS<br/>[FR] UTILISATION DE 1-THIA-DIBENZO[E,H]AZULENES POUR LA PREPARATION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT ET A LA PREVENTION DES MALADIES ET DES TROUBLES DU SYSTEME NERVEUX CENTRAL
  申请人：PLIVA ISTRAZIVACKI INST D O O

  公开号：WO2005049020A1

  公开（公告）日：2005-06-02

  The present invention relates to the use of derivatives from the group of 1-thia-3-aza­dibenzo[e,h]azulenes and of their pharmaceutically acceptable salts and solvates for the manufacture of a pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other neurotransmitters.